Moreover, the 36-month beta value for PHVS is -3.13. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 1 as “sell.”
The public float for PHVS is 17.01M and currently, short sellers hold a 1.08% of that float. On November 28, 2024, PHVS’s average trading volume was 105.90K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PHVS) stock’s latest price update
Pharvaris NV (NASDAQ: PHVS)’s stock price has dropped by -7.47 in relation to previous closing price of 24.17. Nevertheless, the company has seen a gain of 9.07% in its stock price over the last five trading days. globenewswire.com reported 2024-11-13 that ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced financial results for the third quarter ended September 30, 2024, and highlighted recent business updates.
PHVS’s Market Performance
Pharvaris NV (PHVS) has seen a 9.07% rise in stock performance for the week, with a -5.85% decline in the past month and a 29.25% surge in the past quarter. The volatility ratio for the week is 10.09%, and the volatility levels for the past 30 days are at 7.45% for PHVS. The simple moving average for the past 20 days is 0.81% for PHVS’s stock, with a 8.60% simple moving average for the past 200 days.
Analysts’ Opinion of PHVS
Many brokerage firms have already submitted their reports for PHVS stocks, with Wedbush repeating the rating for PHVS by listing it as a “Outperform.” The predicted price for PHVS in the upcoming period, according to Wedbush is $27 based on the research report published on September 25, 2023 of the previous year 2023.
Morgan Stanley, on the other hand, stated in their research note that they expect to see PHVS reach a price target of $34, previously predicting the price at $10. The rating they have provided for PHVS stocks is “Overweight” according to the report published on August 15th, 2023.
Bryan Garnier gave a rating of “Buy” to PHVS, setting the target price at $16 in the report published on October 05th of the previous year.
PHVS Trading at 6.59% from the 50-Day Moving Average
After a stumble in the market that brought PHVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.24% of loss for the given period.
Volatility was left at 7.45%, however, over the last 30 days, the volatility rate increased by 10.09%, as shares sank -9.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.37% upper at present.
During the last 5 trading sessions, PHVS rose by +9.07%, which changed the moving average for the period of 200-days by -18.69% in comparison to the 20-day moving average, which settled at $22.18. In addition, Pharvaris NV saw -20.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHVS starting from PENG LU, who proposed sale 15,000 shares at the price of $24.80 back on Oct 31 ’24. After this action, PENG LU now owns shares of Pharvaris NV, valued at $372,000 using the latest closing price.
PENG LU, the Officer of Pharvaris NV, proposed sale 17,000 shares at $22.21 during a trade that took place back on Oct 24 ’24, which means that PENG LU is holding shares at $377,570 based on the most recent closing price.
Stock Fundamentals for PHVS
The total capital return value is set at -0.3. Equity return is now at value -58.16, with -54.26 for asset returns.
Currently, EBITDA for the company is -96.85 million with net debt to EBITDA at 2.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.08.
Conclusion
To wrap up, the performance of Pharvaris NV (PHVS) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
